Meeting the Unmet Needs in HCV Treatment: A Quality Improvement Program
Hepatitis C (HCV) is a major health problem. It can lead to cirrhosis, liver failure, or liver cancer and is the nation’s leading reason for liver transplants. This illness now causes more deaths than HIV in the United States. HCV is particularly a problem for baby boomers; nearly 75 percent of Americans with hepatitis C were born between 1945 and 1965. Effective treatment is vital to cure patients and prevent progression and deaths from cirrhosis and liver cancer.
With that in mind Duke Medicine, one of the world leaders in HCV care, has created a Performance Improvement/Quality Improvement initiative with a goal to address the unmet needs in HCV treatment. Central to this effort is the utilization of expert knowledge, technology and expertise in successfully implementing QI models to drive population health improvement.
The program features baseline knowledge about the care of the patient with Hepatitis C, including a review of the pathophysiology of Hepatitis C, the recommended quality and performance metrics, and the systemic or patient challenges that a healthcare provider might face during the care of Hepatitis C patients. Participants will also learn about new DAA therapies and other soon-to-be released Hepatitis C treatments; including how to implement the new agents, review of the specific treatment algorithms as approved by the FDA, monitoring for side effects, and challenges of timing viral load determinations. Duke Clinical Director for Hepatology Andrew Muir, MD, will act as activity medical director for this program.
Please click the ENROLL IN PI button to enroll and start the activity.
- 20.00 AMA PRA Category 1 Credit™